Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer

• Status: Terminated
• Trial end date: 2014-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

Patients with triple negative metastatic breast cancer (HER2-, PR-, ER-) will receive bevacizumab, paclitaxel and capecitabine as a first line of treatment (possibility to have received adjuvant chemotherapy).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ARCAGY/ GINECO GROUP
• Treatments: Albumin-Bound Paclitaxel; Bevacizumab; Capecitabine; Paclitaxel

Criteria

Inclusion Criteria:

• Female histologically confirmed adenocarcinoma of the breast ER-, PR-, HER2- disease

• Measurable disease

• Patients may received prior radiotherapy as adjuvant treatment or/and metastatic disease provided that they have progressive disease at study entry

Exclusion Criteria:

• Prior chemotherapy for metastatic disease

• HER2 positive and/or hormonal receptor positive